Abstract:Abstract When introduced for advanced BRAF-V600E-positive melanoma in 2011, BRAF inhibitor monotherapy cutaneous adverse effects included development of cutaneous squamous cell carcinoma (cSCC), eruptive melanocytic naevi (EMN) and melanoma. These risks became significantly less common when combination BRAF inhibitor/MEK inhibitor therapy became standard of care. However, in recent years BRAF inhibitor monotherapy is once again being used for other BRAF-V600E-positive malignancies. We report the first case of florid EMN developing on encorafenib BRAF inhibitor monotherapy for colorectal cancer, which dramatically regressed upon its withdrawal. A 62-year-old female patient with BRAF-V600E metastatic colorectal cancer was started on dual cetuximab (epidermal growth factor receptor inhibitor) and encorafenib therapy. Within 2–3 months > 40 new darkly pigmented melanocytic naevi had developed on her palms, soles, face and trunk. None were clinically or dermoscopically suspicious for melanoma. Treatment was continued given the initial partial response of the colorectal tumour. However, by 6 months this had progressed; cetuximab and encorafenib were stopped and chemotherapy started with FOLFIRI (folinic acid, fluorouracil and irinotecan). Within 2–3 months of encorafenib withdrawal, the EMN were involuting. Twelve months after stopping encorafenib, there had been almost complete involution of all EMN while pre-existing naevi remained stable. Excisional biopsy of a regressing lesion confirmed a benign melanocytic naevus with no dysplasia. Encorafenib is a highly selective RAF kinase inhibitor, which blocks the activated downstream mitogen-activated protein kinase (MAPK)-signalling pathway in BRAF-V600E mutant cells. However, in BRAF-wildtype melanocytes, BRAF-inhibitor monotherapy can cause paradoxical activation of MAPK signalling, promoting melanocytic hyperproliferation and development of new melanocytic naevi, EMN and primary melanomas. It is postulated that with ongoing BRAF inhibitor exposure, EMN become dependent upon activated MAPK signalling. This view is supported by reports of BRAF inhibitor monotherapy-associated EMN that subsequently undergo involution when MEK inhibitors are started. However, to our knowledge, there are no reports of spontaneous involution of EMN when BRAF inhibitor monotherapy alone is stopped, as in our case. This may not have been evident in historic cohorts of patients with advanced melanoma who had poor survival rates once BRAF inhibitor resistance developed. We hypothesize that EMN involution reflects reversal rather than blockade of MAPK pathway activation. In summary, we report the first case of EMN associated with BRAF inhibitor monotherapy to demonstrate complete involution upon treatment withdrawal. Given increasing use of BRAF inhibitor monotherapy as part of treatment regimens for patients with BRAF-V600E-positive cancers other than melanoma, this is likely to become a more common problem in the future. These risks will potentially extend to invasive cSCC and melanoma and highlight the central importance of supportive dermato-oncology expertise in ensuring clinician and patient awareness and appropriate ongoing skin surveillance.

Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib

A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with dabrafenib and trametinib evidenced by an algorithm-defined pyrexia score.

The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective Study

Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors

Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma

Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series

Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2

BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report

Early onset drug-induced hypersensitivity syndrome with lymphopenia, hepatitis, and normal eosinophils induced by BRAF/MEK inhibitor after immune checkpoint inhibitor therapy

Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma

Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors

BI04 Erupting and spontaneously vanishing moles in a new cohort of patients on BRAF inhibitor monotherapy

Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors

Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution

P683Cardiovascular adverse events associated with BRAF and MEK inhibitors

Case Report: Balancing immune responses - multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4 + naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer

Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study